Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.53 |
| ▸ | CDK2AP1 | O14519 | 3/20 | 0.53 |
| ▸ | PBK | Q96KB5 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278935 | 1.00 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2GLACHEK1 | |
| SCHEMBL1278937 | 1.00 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2GLACHEK1 | |
| Hydrochloric Acid SCHEMBL4937740 | 0.90 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2GLAPBK | |
| SCHEMBL13161968 | 0.85 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GLAPOLB | |
| SCHEMBL13162659 | 0.84 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2GLAPOLB | |
| SCHEMBL13162641 | 0.84 | NPC1 (0.90) | NPC1RAB9ASMN1; SMN2GLAPOLB | |
| SCHEMBL29392153 | 0.83 | CHEK1 (0.56) | CHEK1CDK2AP1PBKPARP1 | |
| SCHEMBL7673369 | 0.83 | CHEK1 (0.56) | CHEK1CDK2AP1PBKPARP1 | |
| SCHEMBL31227213 | 0.83 | CHEK1 (0.60) | CHEK1CDK2AP1PBKPARP1 | |
| SCHEMBL5654175 | 0.83 | CHEK1 (0.60) | CHEK1CDK2AP1PBKPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010096703-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM5, CHRM2 | NPC1 1646/4885RAB9A 1694/4885SMN1; SMN2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.